Report : Europe Non-Alcoholic Steatopatitis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)
Treatment Segment to Dominate Europe Non-Alcoholic Steatohepatitis market Forecast to 2028 during 2019–2028
According to a new market research study on the Europe Non-Alcoholic Steatohepatitis market Forecast to 2028 –– by product, application, sales channel and countries is expected to reach US$ 12,963.42 million by 2028 from US$ 838.07 million in 2021. The market is estimated to grow at a CAGR of 47.9% from 2021 to 2028. The report provides trends prevailing in the Europe Non-Alcoholic Steatohepatitis market along with the drivers and restraints pertaining to the market growth. Rising prevalence of NASH is the major factor driving the growth of the Europe Non-Alcoholic Steatohepatitis market. However, issues associated with stringent regulations related to Non-Alcoholic Steatohepatitis the growth of Europe Non-Alcoholic Steatohepatitis market.
The Europe Non-Alcoholic Steatohepatitis market segmented into product, application, sales channel and country. Based on product type the Europe Non-Alcoholic Steatohepatitis market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period..Based on application the Europe Non-Alcoholic Steatohepatitis market segmented into treatment and diagnosis. The treatment segment is dominated Europe Non-Alcoholic Steatohepatitis market in 2020. Based on sales channel the Europe Non-Alcoholic Steatohepatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated EuropeNon-Alcoholic Steatohepatitis market in 2020. Based on country, the Europe Non-Alcoholic Steatohepatitis market segmented into Germany, U.K, France, Italy, Spain, Rest of Europe. The Germany is dominated the Europe Non-Alcoholic Steatohepatitis market in 2020.
Cadila Pharmaceutical,Intercept Pharmaceutical,Novartis AG,Galmed Pharmaceutical,GENFIT, ONE WAY LIVER SI, BioPredictive S.A.S, Siemens Healthineers AG and Laboratory Corporation of America Holdings are among the leading companies in the Europe Non-Alcoholic Steatohepatitis market. For instance, Nov-2021 GENFIT announced that its NIS4 technology has been recognized in a Stage 1 study1 undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium as demonstrating a unique performance in identifying patients with “at-risk” Non-Alcoholic Steatohepatitis (NASH). The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in dynamic market.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: sales@businessmarketinsights.com